European Journal of Cancer
Volume 41, Issue 6 , Pages 922-931 , April 2005

Quality of life in prostate cancer

  • James A. Talcott

      Affiliations

    • Massachusetts General Hospital, Center for Outcomes Research, Massachusetts General Cancer Centre, 75 Blossom St., Suite 230, Boston, MA 02114-2696, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 724 5451; fax: +1 617 724 5457
    • ,
  • Jack A. Clark

      Affiliations

    • Boston University School of Public Health, Boston, MA, USA

Received 6 October 2004 ,Accepted 2 December 2004.

References 

  1. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  2. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer. 1973;32:1126–1130
  3. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma [published erratum appears in N Engl J Med 1989 Nov 16;321(20):1420]. N Engl J Med. 1989;321:419–424
  4. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998;339:1036–1042
  5. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol. 1997;15:1013–1021
  6. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22:2927–2941
  7. Talcott JA. Androgen deprivation as primary treatment for early prostate cancer: should we “Just Do Something”. J Natl Cancer Inst. 2002;94:407–409
  8. Moore MJ, O’Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol. 1988;6:1736–1745
  9. Fowler FJ, McNaughton Collins M, Albertsen PC, et al. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer [see comments]. JAMA. 2000;283:3217–3222
  10. Mills N, Donovan JL, Smith M, et al. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials. 2003;24:272–282
  11. Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001;166:1702–1706
  12. Donovan J, Mills N, Smith M, et al. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ. 2002;325:766–770
  13. Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001–4008
  14. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  15. Michaelson MD, Talcott JA, Smith MR. Prostate cancer: metastatic. Clin Evid. 2002;881–890
  16. Pietrow PK, Parekh DJ, Smith JA, et al. Health related quality of life assessment after radical prostatectomy in men with prostate specific antigen only recurrence. J Urol. 2001;166:2286–2290
  17. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764
  18. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590–597
  19. Tannock IF. False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. J Natl Cancer Inst. 1996;88:206–207
  20. McHorney CA, Ware JE, Raczek AE. The MOS36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263
  21. McNair DM, Lorr M, Droppleman LF. Profile of Mood States. 2nd ed.. San Diego: Educational and Industrial Testing Service; 1981;
  22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  23. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  24. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981;34:585–597
  25. Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2:472–483
  26. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012
  27. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905
  28. Stockler MR, Osoba D, Corey P, et al. Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire. J Clin Epidemiol. 1999;52:653–666
  29. Dale W, Campbell T, Ignacio L, et al. Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms. Urology. 1999;53:359–366
  30. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27:S217–S232
  31. Talcott JA, Manola J, Clark JA, et al. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003;21:3979–3986
  32. Clark JA, Inui TS, Silliman RA, et al. Patients’ perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol. 2003;21:3777–3784
  33. Ganz PA, Schag CA, Lee JJ, et al. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res. 1992;1:19–29
  34. Akakura K, Isaka S, Akimoto S, et al. Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology. 1999;54:313–318
  35. Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer. 2001;92:3111–3119
  36. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  37. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–796
  38. Auvinen A, Vornanen T, Tammela TL, et al. A randomized trial of the choice of treatment in prostate cancer: design and baseline characteristics. BJU Int. 2001;88:708–715
  39. Rosenberg HJ, Rosenberg SD, Ernstoff MS, et al. Expressive disclosure and health outcomes in a prostate cancer population. Int J Psychiatry Med. 2002;32:37–53
  40. McHorney CA, Ware JE, Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40–66
  41. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370
  42. Johansson JE, Wersall P, Brandberg Y, et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer – a randomized study. Scand J Urol Nephrol. 2001;35:288–294
  43. Boccardo F, Rubagotti A, Barichello M, et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol. 1999;17:2027–2038
  44. Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19:62–71
  45. Fossa SD, Curran D, Aaronson NK, et al. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893. Eur Urol. 2000;37:541–551
  46. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998;90:1537–1544
  47. Sharp LK, Knight SJ, Nadler R, et al. Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res. 1999;8:461–470
  48. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860–864
  49. Clark JA, Talcott JA. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care. 2001;39:1118–1130
  50. Bokhour BG, Clark JA, Inui TS, et al. Sexuality after treatment for early prostate cancer: exploring the meanings of erectile dysfunction. J Gen Intern Med. 2001;16:649–655
  51. Clark JA, Wray N, Brody B, et al. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med. 1997;45:1299–1309
  52. Litwin MS, Pasta DJ, Yu J, et al. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2000;164:1973–1977
  53. Litwin MS, Flanders SC, Pasta DJ, et al. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1999;54:503–508
  54. Beard CJ, Propert KJ, Rieker PP, et al. Complications after treatment with external-beam irradiation in early stage prostate cancer patients: a prospective multiinstitutional outcomes study. J Clin Oncol. 1997;15:223–229
  55. Albertsen PC, Aaronson NK, Muller MJ, et al. Health-related quality of life among patients with metastatic prostate cancer. Urology. 1997;49:207–216discussion 216–217
  56. Litwin MS, Shpall AI, Dorey F, et al. Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol. 1998;21:327–332
  57. Kim SP, Bennett CL, Chan C, et al. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Huntingt). 1999;13:823–832
  58. Penson DF, Stoddard ML, Pasta DJ, et al. The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol. 2001;54:350–358
  59. Clark JA, Rieker P, Propert KJ, et al. Changes in quality of life following treatment for early prostate cancer. Urology. 1999;53:161–168
  60. Bacon CG, Giovannucci E, Testa M, et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002;94:862–871
  61. Davis JW, Kuban DA, Lynch DF, et al. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol. 2001;166:947–952
  62. Curran D, Fossa S, Aaronson N, et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), genito-urinary tract cancer cooperative group (GUT-CCG). Eur J Cancer. 1997;33:1809–1814E[corrected to Keuppens F]
  63. Tefilli MV, Gheiler EL, Tiguert R, et al. Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. J Surg Oncol. 1998;69:156–161
  64. Joly F, Brune D, Couette JE, et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol. 1998;9:751–757
  65. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al. Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer. 1997;79:1977–1986
  66. Fossa SD, Woehre H, Kurth KH, et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol. 1997;31(Suppl 3):3–8
  67. Krupski T, Petroni GR, Bissonette EA, et al. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology. 2000;55:736–742
  68. Sprangers MA, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC quality of life study group. Qual Life Res. 1998;7:291–300
  69. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30. Qual Life Res. 1996;5:212–222
  70. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928
  71. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233
  72. Cella DF, Jacobsen PB, Orav EJ, et al. A brief POMS measure of distress for cancer patients. J Chronic Dis. 1987;40:939–942
  73. Kemmler G, Holzner B, Kopp M, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932–2940
  74. Herr HW, O’Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol. 2000;163:1743–1746
  75. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36:1134–1141
  76. Monga U, Kerrigan AJ, Thornby J, et al. Prospective study of fatigue in localized prostate cancer patients undergoing radiotherapy. Radiat Oncol Investig. 1999;7:178–185
  77. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62:1034–1038
  78. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129–135
  79. Barry MJ, Fowler FJ, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557
  80. Stewart A, Ware JEJ. Measuring functioning and well-being: The Medical Outcomes Study approach. Durham, NC: Duke University Press; 1992;
  81. O’Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology. 1995;46:697–706
  82. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830
  83. Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000;18:1440–1450
  84. Clark JA, Bokhour BG, Inui TS, et al. Measuring patients’ perceptions of the outcomes of treatment for early prostate cancer. Med Care. 2003;41:923–936
  85. Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer results of a prospective cohort study. J Clin Oncol. 1998;16:275–283
  86. Lubeck DP, Litwin MS, Henning JM, et al. Changes in health-related quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology. 1999;53:180–186
  87. Seo PH, D’Amico AV, Clark JA, et al. Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment. Clin Prostate Cancer. 2004;3:38–42
  88. Litwin MS, Talcott JA. Quality of life in prostate cancer: past, present, future. In: Lipscomb J, Gotay CC, Snyder C, editors. Outcomes assessment in cancer. Cambridge: Cambridge University Press; 2003 (in press)

PII: S0959-8049(05)00055-9

doi: 10.1016/j.ejca.2004.12.030

European Journal of Cancer
Volume 41, Issue 6 , Pages 922-931 , April 2005

Article Tools